NRx Pharmaceuticals To Proceed With Two New Drug Applications In 2024; NRX-101 Returned To Company For Filing
$NRXP
Biotechnology: Pharmaceutical Preparations
Health Care
- New Drug Application (NDA) for Accelerated Approval planned for NRX-101 in people with bipolar depression and akathisia in 2024, based on two positive trials 1 2 and Breakthrough Therapy Designation. Potential revenue in 2025
- NDA for NRX-100 (IV ketamine) in suicidal depression in advanced preparation for submission in 2024; based on four positive trials 3 4 5 6 and Fast Track Designation. Potential revenue in 2025
- Gaining these approvals has the potential to yield more than $150 in revenue per NRXP share in the near term, at current share count
- Planning for HOPE Therapeutics share distribution progresses; audit nearing completion – critical step towards a public listing